CoChat
Sign Up
Cited by 386Multiple Myeloma Research and TreatmentsBone health and treatmentsProtein Degradation and Inhibitors

The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Open access
Richardson, Paul G, Oriol, Albert, Beksac, Meral, Liberati, Anna Marina, Galli, Monica, Schjesvold, Fredrik, Lindsay, Jindriska, Weisel, Katja, White, Darrell, Facon, Thierry, San Miguel, Jesus, Sunami, Kazutaka, O'Gorman, Peter, Sonneveld, Pieter, Robak, Pawel, Semochkin, Sergey, Schey, Steve, Yu, Xin, Doerr, Thomas, Bensmaine, Amine, Biyukov, Tsvetan, Peluso, Teresa, Zaki, Mohamed, Anderson, Kenneth, Dimopoulos, Meletios, Abildgaard, Niels, Adler, Howard, Altuntas, Fevzi, Akay, Olga Meltem, Amin, Bipinkumar, Anagnostopoulos, Achilleas, Anderson, Larry, Anttila, Pekka, Araujo, Carla, Arce-Lara, Carlos, Aydin, Yildiz, Basu, Supratik, Battini, Ramakrishna, Beeker, Thaddeus, Benboubker, Lotfi, Ben-Yehuda, Dina, Bladé, Joan, Blau, Igor Wolfgang, Boccia, Ralph, Burke, Lillian, Byeff, Peter, Cascavilla, Nicola, Cavo, Michele, Chantry, Andrew, Charles, Yen, Chaudhry, Arvind, Corso, Alessandro, Coyne, Mark, De Arriba, Felipe, Delimpasi, Sosana, Desjardins, Pierre, Dhakal, Binod, Di Bartolomeo, Paolo, Di Raimondo, Francesco, Dürig, Jan, Engelhardt, Monika, Escoffre-Barbe, Martine, Esteves, Graca, Flogegard, Max, Gabrail, Nashat, Gamberi, Barbara, Garrison, Mitchell, Gay, Julie, Gisslinger, Heinz, Goldschmidt, Hartmut, Goncalves, Cristina, Gressot, Laurent, Grosicki, Sebastian, Hanna, Wahid, Hayden, Patrick, Henriques Bernardo, Maria Manuela, Hermann, Robert, Holden, Viran, Honkalehto, Kirsti, Huben, Marianne, Huffman, John, Hunter, Hannah, Hus, Marek, Jagasia, Madan, Jagganath, Sundar, Janakiram, Murali, Jaiyesimi, Ishmael, Jenner, Matthew, João, Cristina, Johnson, Peter, Jurcyszyn, Artur, Kalayoğlu Beşişik, Sevgi, Kambhampati, Suman, Kanate, Abraham, Karadoğan, Ihsan, Khojasteh, Ali, Kirkel, Dean, Komarnicki, Mieczyslaw, Krauth, Maria-Theresa, Kuriakose, Phillip, Larocca, Alessandra, Lauri, Birgitta, Leleu, Xavier, Lucio, Paulo, Luppi, Mario, Mangiacavalli, Silvia, Mariette, Clara, Matsue, Kosei, Mellqvist, Ulf-Henri, Mendeleeva, Larisa, Meshad, Michael, Miller, Carole, Mohrbacher, Ann, Moreau, Philippe, Morelli, Anna Maria, Müldür, Ercan, Naassan, Anthony, Nahi, Hareth, Nair, Rajesh, O'Dwyer, Mike, Öngören Aydin, Seniz, Openshaw, Thomas, O'Rourke, Timothy, Osswald, Michael, Overton, Lindsay, Pati, Asmin, Pavic, Michel, Pegourie, Brigitte, Pehlivan, Mustafa, Pierola, Ana Alfonso, Plesner, Torben, Pluta, Andrzej, Rabin, Neil, Ramasamy, Karthik, Rambaldi, Alessandro, Rodriguez, Paula, Röllig, Christoph, Rosenblatt, Jacalyn, Rosenbluth, Jonathan, Salomo, Morten, Samoylova, Olga, Sastre Moral, Jose, Sati, Hamdi, Selleri, Carmine, Shafeek, Salim, Shinagawa, Atsushi, Sleckman, Bethany, Smith, Clay, Sonmez, Mehmet, Stone, Chester, Streetly, Matthew, Suzuki, Kenshi, Taetle, Raymond, Tafuri, Agostino, Takezako, Naoki, Teke, Hava Üsküdar, Vapaatalo, Mirja, Vassilopoulos, George, Verma, Amit, Vidito, Sarah, Viterbo, Luisa, Vural, Filiz, Wang, Xiang Sean, Yağci, Munci, Yee, Andrew·2019·The Lancet Oncology
DOI 10.1016/s1470-2045(19)30152-4
Open this paper in CoChat — free account

Abstract

Background As lenalidomide becomes increasingly established for upfront treatment of multiple myeloma, patients refractory to this drug represent a population with an unmet need. The combination of pomalidomide, bortezomib, and dexamethasone has shown promising results in phase 1/2 trials of patients with relapsed or refractory multiple myeloma. We aimed to assess the efficacy and safety of this triplet regimen in patients with relapsed or refractory multiple myeloma who previously received lenalidomide. Methods We did a randomised, open-label, phase 3 trial at 133 hospitals and research centres in 21 countries. We enrolled patients (aged ≥18 years) with a diagnosis of multiple myeloma and measurable disease, an Eastern Cooperative Oncology Group performance status of 0-2, who received one to three previous regimens, including a lenalidomide-containing regimen for at least two consecutive cycles. We randomly assigned patients (1:1) to bortezomib and dexamethasone with or without pomalidomide using a permutated blocked design in blocks of four, stratified according to age, number of previous regimens, and concentration of β 2 microglobulin at screening. Bortezomib (1·3 mg/m 2) was administered intravenously until protocol amendment 1 then either intravenously or subcutaneously on days 1, 4, 8, and 11 for the first eight cycles and subsequently on days 1 and 8. Dexamethasone (20 mg [10 mg if age >75 years]) was administered orally on the same days as bortezomib and the day after. Patients allocated pomalidomide received 4 mg orally on days 1-14. Treatment cycles were every 21 days. The primary endpoint was progression-free survival in the intention-to-treat population, as assessed by an independent review committee. Safety was assessed in all patients who received at least one dose of study medication. This trial is registered at ClinicalTrials.gov, number NCT01734928; patients are no longer being enrolled. Findings Between Jan 7, 2013, and May 15, 2017, 559 patients were enrolled. 281 patients were assigned pomalidomide, bortezomib, and dexamethasone and 278 were allocated bortezomib and dexamethasone. Median follow-up was 15·9 months (IQR 9·9-21·7). Pomalidomide, bortezomib, and dexamethasone significantly improved progression-free survival compared with bortezomib and dexamethasone (median 11·20 months [95% CI 9·66-13·73] vs 7·10 months [5·88-8·48]; hazard ratio 0·61, 95% CI 0·49-0·77; p<0·0001). 278 patients received at least one dose of pomalidomide, bortezomib, and dexamethasone and 270 patients received at least one dose of bortezomib and dexamethasone, and these patients were included in safety assessments. The most common grade 3 or 4 treatment-emergent adverse events were neutropenia (116 [42%] of 278 patients vs 23 [9%] of 270 patients; nine [3%] vs no patients had febrile neutropenia), infections (86 [31%] vs 48 [18%]), and thrombocytopenia (76 [27%] vs 79 [29%]). Serious adverse events were reported in 159 (57%) of 278 patients versus 114 (42%) of 270 patients. Eight deaths were related to treatment; six (2%) were recorded in patients who received pomalidomide, bortezomib, and dexamethasone (pneumonia [n=2], unknown cause [n=2], cardiac arrest [n=1], cardiorespiratory arrest [n=1]) and two (1%) were reported in patients who received bortezomib and dexamethasone (pneumonia [n=1], hepatic encephalopathy [n=1]). Interpretation Patients with relapsed or refractory multiple myeloma who previously received lenalidomide had significantly improved progression-free survival when treated with pomalidomide, bortezomib, and dexamethasone compared with bortezomib and dexamethasone. Adverse events accorded with the individual profiles of pomalidomide, bortezomib, and dexamethasone. This study supports use of pomalidomide, bortezomib, and dexamethasone as a treatment option in patients with relapsed or refractory multiple myeloma who previously received lenalidomide. Funding Celgene.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(19)30152-4

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 39 references

Cited by

Sorted by citations

See all 386

Related

Metadata

Authors
Richardson, P. G., Oriol, A., Beksac, M., Liberati, A. M., Galli, M., Schjesvold, F., Lindsay, J., Weisel, K., White, D., Facon, T., San Miguel, J., Sunami, K., O'Gorman, P., Sonneveld, P., Robak, P., Semochkin, S., Schey, S., Yu, X., Doerr, T., Bensmaine, A., Biyukov, T., Peluso, T., Zaki, M., Anderson, K., Dimopoulos, M., Abildgaard, N., Adler, H., Altuntas, F., Akay, O. M., Amin, B., Anagnostopoulos, A., Anderson, L., Anttila, P., Araujo, C., Arce-Lara, C., Aydin, Y., Basu, S., Battini, R., Beeker, T., Benboubker, L., Ben-Yehuda, D., Bladé, J., Blau, I. W., Boccia, R., Burke, L., Byeff, P., Cascavilla, N., Cavo, M., Chantry, A., Charles, Y., Chaudhry, A., Corso, A., Coyne, M., De Arriba, F., Delimpasi, S., Desjardins, P., Dhakal, B., Di Bartolomeo, P., Di Raimondo, F., Dürig, J., Engelhardt, M., Escoffre-Barbe, M., Esteves, G., Flogegard, M., Gabrail, N., Gamberi, B., Garrison, M., Gay, J., Gisslinger, H., Goldschmidt, H., Goncalves, C., Gressot, L., Grosicki, S., Hanna, W., Hayden, P., Henriques Bernardo, M. M., Hermann, R., Holden, V., Honkalehto, K., Huben, M., Huffman, J., Hunter, H., Hus, M., Jagasia, M., Jagganath, S., Janakiram, M., Jaiyesimi, I., Jenner, M., João, C., Johnson, P., Jurcyszyn, A., Kalayoğlu Beşişik, S., Kambhampati, S., Kanate, A., Karadoğan, I., Khojasteh, A., Kirkel, D., Komarnicki, M., Krauth, M.-T., Kuriakose, P., Larocca, A., Lauri, B., Leleu, X., Lucio, P., Luppi, M., Mangiacavalli, S., Mariette, C., Matsue, K., Mellqvist, U.-H., Mendeleeva, L., Meshad, M., Miller, C., Mohrbacher, A., Moreau, P., Morelli, A. M., Müldür, E., Naassan, A., Nahi, H., Nair, R., O'Dwyer, M., Öngören Aydin, S., Openshaw, T., O'Rourke, T., Osswald, M., Overton, L., Pati, A., Pavic, M., Pegourie, B., Pehlivan, M., Pierola, A. A., Plesner, T., Pluta, A., Rabin, N., Ramasamy, K., Rambaldi, A., Rodriguez, P., Röllig, C., Rosenblatt, J., Rosenbluth, J., Salomo, M., Samoylova, O., Sastre Moral, J., Sati, H., Selleri, C., Shafeek, S., Shinagawa, A., Sleckman, B., Smith, C., Sonmez, M., Stone, C., Streetly, M., Suzuki, K., Taetle, R., Tafuri, A., Takezako, N., Teke, H. Ü., Vapaatalo, M., Vassilopoulos, G., Verma, A., Vidito, S., Viterbo, L., Vural, F., Wang, X. S., Yağci, M., & Yee, A.
Affiliations
  • Harvard University (US)
  • Josep Carreras Leukaemia Research Institute (ES)
  • University of Perugia (IT)
  • Ospedale Papa Giovanni XXIII (IT)
  • Oslo University Hospital (NO)
  • East Kent Hospitals University NHS Foundation Trust (GB)
  • University Medical Center Hamburg-Eppendorf (DE)
  • Dalhousie University (CA)
  • Université de Lille (FR)
  • National Hospital Organization (JP)
  • Erasmus MC Cancer Institute (NL)
  • Medical University of Lodz (PL)
  • King's College London (GB)
  • Celgene (United States) (US)
  • National and Kapodistrian University of Athens (GR)
  • University College Dublin (IE)
Corresponding author
Richardson, Paul G
ORCID
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2019-06
Volume
20
Issue
6
Pages
781-794
ISSN
1470-2045 (ISSN-L)
DOI
10.1016/s1470-2045(19)30152-4
OpenAlex
W2945852816
Cited by
386
References
39
Citations by year
2026: 24 · 2025: 50 · 2024: 42 · 2023: 61 · 2022: 59 · 2021: 71 · 2020: 55 · 2019: 21
FWCI
35.93
Type
journal article
Language
en
Open access
Licence
Locations
  • The Lancet Oncology (publishedVersion)
  • PubMed (publishedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
  • University of Southern Denmark Research Portal (University of Southern Denmark) (publishedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
  • Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
  • IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
  • Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
  • Research Portal (King's College London) (submittedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
Funders
Celgene
Topics
  • Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
  • Health Sciences › Medicine › Oncology › Bone health and treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
Keywords
relapsed/refractory multiple myeloma, pomalidomide, bortezomib, dexamethasone, lenalidomide-refractory disease, progression-free survival, overall survival, treatment safety, triplet regimens, beta2-microglobulin, proteasome inhibitor combination, treatment-emergent adverse events
MeSH terms
Bortezomib, Lenalidomide, Adolescent, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Female, Follow-Up Studies, Humans, Male, Middle Aged, Multiple Myeloma, Neoplasm Recurrence, Local, Prognosis, Thalidomide, Survival Rate, Salvage Therapy, Drug Resistance, Neoplasm, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review